Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Sokolove Jeremy Brett 2. Date of Event Requiring Statement (Month/Day/Year) 04/01/2026 3. Issuer Name and Ticker or Trading Symbol Vor Biopharma Inc. [VOR] (Last) (First) (Middle) 500 BOYLSTON STREET, SUITE 1350 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Medical Officer 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) BOSTON, MA 02116 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 27,900(1) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(2)	10/31/2035	Common Stock	130,100	$8.18(3)	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Sokolove Jeremy Brett 500 BOYLSTON STREET, SUITE 1350 BOSTON, MA 02116			Chief Medical Officer

Signatures

/s/ Adi Osovsky Attorney-in-Fact		04/09/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. 1/4th of the RSUs shall vest on November 1, 2026, with the remainder vesting in substantially equal quarterly installments over the following 3 years, in each case subject to the Reporting Person's continued service as of each such vesting date.
(2)	1/4th of the shares underlying the option vest on November 1, 2026, with the remainder vesting in substantially equal monthly installments over the following 3 years, in each case subject to the Reporting Person's continued service as of each such vesting date.
(3)	On December 5, 2025, the Issuer's Board of Directors approved a stock option award repricing, pursuant to which the exercise price was reduced to $8.18. Under the terms of the stock option award repricing, the exercise price of this award will revert to $24.11 if the option is exercised prior to the earliest of (i) December 5, 2027; (ii) a Change in Control during the option holder's Continuous Service (each as defined in the Issuer's 2023 Inducement Plan); and (iii) 30 days prior to the option's original expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.